Avoro Capital Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Avoro Capital Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-625,000	Closed	-$82.5M	–	34
2025 Q1	$82.5M	Sell	625,000 -2,425,000	-80%	-$302M	1.29%	18
2024 Q4	$255M	Hold	3,050,000	–	–	3.6%	8
2024 Q3	$223M	Buy	3,050,000 +50,000	+2%	+$3.76M	3.25%	10
2024 Q2	$205M	Buy	3,000,000 +525,000	+21%	+$36.4M	2.74%	15
2024 Q1	$171M	Buy	2,475,000 +219,445	+10%	+$15.1M	2%	18
2023 Q4	$162M	Buy	+2,255,555	New	+$130M	2.23%	16

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Avoro Capital Advisors's ITCI Position: Q2 2025 in Review

Avoro Capital Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 625,000 shares — an estimated $82.5M sold.

Avoro Capital Advisors first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $255M in Q4 2024. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Avoro Capital Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Avoro Capital Advisors sold 625,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $82.5M.
Avoro Capital Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
Avoro Capital Advisors's Intra-Cellular Therapies Inc. position peaked at $255M in Q4 2024.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Avoro Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.